Suppr超能文献

恶性纤维组织细胞瘤的不断演变的概念和管理挑战。

The evolving conception and management challenges of malignant fibrous histiocytoma.

机构信息

Department of Dermatology, Stanford University, 360 Stanford Ave., Palo Alto, CA 94306, USA.

出版信息

Dermatol Surg. 2012 Dec;38(12):1922-9. doi: 10.1111/j.1524-4725.2012.02538.x. Epub 2012 Aug 9.

Abstract

BACKGROUND

Malignant fibrous histiocytoma (MFH) is a rare and aggressive tumor. Mohs micrographic surgery (MMS) has been reported as an effective treatment, although most cases were published before advances in cytopathologic techniques led to reclassification of many tumors.

OBJECTIVE

To evaluate a contemporary cohort of individuals with MFH and analyze management practices.

METHODS

We reviewed all cases of MFH diagnosed at our institution from January 1995 to December 2010, evaluating 839 records to identify 36 patients undergoing management of tumors of the head and neck.

RESULTS

Seventeen of the total 36 patients (47%; mean age 67) experienced tumor recurrence, and 10 (28%) developed metastases. Seven of nine patients initially treated with MMS (78%), and 10 of 24 (42%) treated with WLE experienced recurrence (p = .06). Patients treated with MMS had smaller tissue defects after surgery. The mean contemporary recurrence rate of MFH treated with MMS is significantly higher (58.8%) than the cumulative recurrence rate reported before 2000 (7.4%) (p < .001).

CONCLUSIONS

Our study is consistent with reports of MFH as an aggressive neoplasm and describes the largest population treated with MMS in 3 decades. The changing conception of MFH, along with a propensity for in-transit metastases, may explain higher contemporary recurrence rates.

摘要

背景

恶性纤维组织细胞瘤(MFH)是一种罕见且侵袭性的肿瘤。Mohs 显微外科手术(MMS)已被报道为一种有效的治疗方法,尽管大多数病例是在细胞病理学技术进步导致许多肿瘤重新分类之前发表的。

目的

评估一组当代患有 MFH 的患者,并分析其治疗方法。

方法

我们回顾了我们机构 1995 年 1 月至 2010 年 12 月期间诊断的所有 MFH 病例,评估了 839 份记录,以确定 36 例头颈部肿瘤患者的治疗情况。

结果

36 例患者中有 17 例(47%;平均年龄 67 岁)经历了肿瘤复发,10 例(28%)发生了转移。9 例初始接受 MMS 治疗的患者中有 7 例(78%),24 例接受 WLE 治疗的患者中有 10 例(42%)复发(p=0.06)。接受 MMS 治疗的患者术后组织缺损较小。接受 MMS 治疗的 MFH 的当代复发率(58.8%)明显高于 2000 年前报告的累积复发率(7.4%)(p<0.001)。

结论

我们的研究与 MFH 是一种侵袭性肿瘤的报道一致,并描述了 30 年来接受 MMS 治疗的最大人群。MFH 概念的变化,以及向转移的倾向,可能解释了更高的当代复发率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验